[HTML][HTML] Post COVID-19 pulmonary fibrosis; a meta-analysis study
Introduction; Pulmonary fibrosis is a frequently reported COVID-19 sequela in which the
exact prevalence and risk factors are yet to be established. This meta-analysis aims to …
exact prevalence and risk factors are yet to be established. This meta-analysis aims to …
Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …
in patients with viral respiratory diseases, and are currently being investigated in trials as …
Convalescent plasma therapy for COVID-19: state of the art
Convalescent plasma (CP) therapy has been used since the early 1900s to treat emerging
infectious diseases; its efficacy was later associated with the evidence that polyclonal …
infectious diseases; its efficacy was later associated with the evidence that polyclonal …
Convalescent plasma may be a possible treatment for COVID-19: A systematic review
Y Wang, P Huo, R Dai, X Lv, S Yuan, Y Zhang… - International …, 2021 - Elsevier
Introduction The coronavirus disease 2019 (COVID-19) pandemic has spread globally.
Therapeutic options including antivirals, anti-inflammatory compounds, and vaccines are still …
Therapeutic options including antivirals, anti-inflammatory compounds, and vaccines are still …
[HTML][HTML] Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks
DJ Wooding, H Bach - Clinical Microbiology and Infection, 2020 - Elsevier
Background There is currently no treatment known to alter the course of coronavirus disease
2019 (COVID-19). Convalescent plasma has been used to treat a number of infections …
2019 (COVID-19). Convalescent plasma has been used to treat a number of infections …
[HTML][HTML] Post covid-19 invasive pulmonary Aspergillosis: a case report
Introduction and importance Several complications after corona viral infection-19 (COVID-
19) have been reported. The study aims is to present a case with post-covid-19 pulmonary …
19) have been reported. The study aims is to present a case with post-covid-19 pulmonary …
Convalescent plasma for people with COVID‐19: a living systematic review
C Iannizzi, KL Chai, V Piechotta… - Cochrane Database …, 2023 - cochranelibrary.com
Background Convalescent plasma may reduce mortality in patients with viral respiratory
diseases, and is being investigated as a potential therapy for coronavirus disease 2019 …
diseases, and is being investigated as a potential therapy for coronavirus disease 2019 …
Clinical outcomes and phylogenetic analysis in reflection with three predominant clades of SARS‐CoV‐2 variants
Background The pandemic of coronavirus disease 2019 (COVID‐19) has a broad spectrum
of clinical manifestations. The severe acute respiratory syndrome coronavirus‐2 (SARS …
of clinical manifestations. The severe acute respiratory syndrome coronavirus‐2 (SARS …
Molecular and computational analysis of spike protein of newly emerged omicron variant in comparison to the delta variant of SARS-CoV-2 in Iraq
PMA Rashid, GF Salih - Molecular biology reports, 2022 - Springer
Abstract Background The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2)
has had a major impact on world health over the last 2 years. The emergence of SARS-CoV …
has had a major impact on world health over the last 2 years. The emergence of SARS-CoV …
The influence of SARS‐C o V‐2 on male reproduction and men's health
Abstract Background SARS‐CoV‐2, the virus responsible for COVID‐19, primarily affects the
respiratory system by targeting the Angiotensin‐converting enzyme 2 (ACE2) receptor and …
respiratory system by targeting the Angiotensin‐converting enzyme 2 (ACE2) receptor and …